Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.

Next Previous
Trial Profile

Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Cyclophosphamide
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Everolimus-LDcyclo

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 May 2017 Status changed from recruiting to completed.
    • 29 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top